OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-12-31-accounts

Company Number 06884476

YORK AGAINST CANCER

A company limited by guarantee and

A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended

31 December 2022

HPH Chartered Accountants 54 Bootham York YO30 7XZ

YORK AGAINST CANCER

CONTENTS

Page
Chairman’s Report 1
Trustees’ Report 2 ‐ 16
Auditor’s Report 17 – 20
Statement of Financial Activities 21
Balance Sheet 22
Cash Flow Statement 23
Notes to the Financial Statements 24 ‐ 34

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2022

We at last started to see the end of restrictions that had severely hampered the valuable work that the Charity undertakes and getting back to being as normal as possible was a great tonic, with the opportunity to once again meet together at various functions and events being a very positive step.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each one of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

A number of projects that were under evaluation last year have progressed. These include a £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, and the start of work on the Leveson Centre, a new cancer support centre located close to our main office at the Community Stadium. We also, at last, managed to source a replacement for the minibus.

Our small office team and mini‐bus drivers continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to support and promote the Charity.

Work of course continues, and the need to look forward and plan for our future funding requirements goes on to ensure we remain focused, and in a position to provide the important services for people touched by cancer – services that remain important as we expand on the outstanding work undertaken in the many areas that the Charity is involved in.

It is 35 years since the Charity was created by Professor Steve Leveson, then a consultant surgeon at St James’ Hospital in Leeds, and fellow surgeon John Craven and University Researcher Dr. Colin Garner. Its longevity is not only down to their vision but is also a testament to the work undertaken by everybody who is or has been involved with the Charity.

Steve Leveson and his Wife Pat remain an integral part of the Charity, and with our committed army of volunteers, our small band of dedicated staff, and our many supporters the Charity remains in good hands.

Ian Yeowart Chair York Against Cancer

www.yorkagainstcancerorg.uk 1

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2022.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: ‐

Achievements and performance

SUPPORT ACTIVITIES

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day‐to‐day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

Services and posts supported by York Against Cancer

The charity continues to support the Citizens Advice North Yorkshire (CANY) in their work with cancer patients in the Scarborough area: ensuring that they receive the help to which they are entitled . The area of specialist help includes the following areas.

www.yorkagainstcancerorg.uk 2

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

ISSUE Pa�ents concerns
· Benefts 97%
· Charitable applica�ons 15%
· Health & CommunityCare 5%
· Debt 2%
· Financial services 4%
· Employment 2%
· Housing 5%
· Travel & Transport 6%

It is hoped we will be able to replicate the above post to be based in York and to operate out of the Leveson Centre.

Supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

Teenage Psychology Support

YAC funds a psychologist who specialises in supporting young people when they or their family is affected by cancer. This service is funded on a need basis, during 2022 the charity spent £11k on this service. The psychologist receives her referrals from Clinical Nurse Specialists, Oncologists and G. P’s.

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time‐consuming and tiring journeys to the hospital in York. During 2022 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

www.yorkagainstcancerorg.uk 3

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

Minibus

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2022 we provided 867 single trips to Leeds – radiotherapy is given daily (Mon‐Fri) and length of treatments can range from 3 to 7 weeks. If the demand is low, we use the YAC car, making the service more efficient and if we need to we use volunteer drivers.

In 2022 we purchased a new Minibus as pictured.

The following are a few comments received from users of the minibus service.

‘Thank you for what you do – your minibus service is amazing and appreciated.’

‘Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.’

‘Thank you for your kindness and help getting to St James hospital.’

The provision of patient transport to Rapid Diagnostic appointments.

Patients needing to access diagnosis appointments quickly are offered a rapid diagnostic appointment, this may not be at their nearest hospital which can create problems with attendance. YAC was approached at the end of 2021 asking if we could help with transport. A proposal was put to the YAC board and during 2022 we provided transport to 36 patients at an approximate cost of £2k.

www.yorkagainstcancerorg.uk 4

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

Respite Properties

The Respite house in Filey continues to provide a welcome break for cancer patients, during 2022 90 patients, their family and friends enjoyed a stay. Many families donate their deposit as way of a thank you and we encourage them to give us feedback, this ensures we hear about their stay and of course so we can act on any improvements needed.

The following are a few comments we have received.

‘We just wanted to say a huge thank you, for making it possible for us all to have a lovely few days together, ‘Thank you for all you do for stress free.’ cancer patients. We had an amazing break and will treasure all the memories.’

‘I cannot thank you enough. My holiday in the Filey house was just what I needed. It has done me the world of good after home alone, lockdown and cancer treatment. My friends and I enjoyed a walk by the sea, strolling around Filey and coming back to a cosy house with a beautiful comforting log fire.’

‘Thank you so much, our stay in Filey was wonderful and beyond our expectations.’

Da Vinci surgical robot.

In 2022 the YAC board were approached by the York and Scarborough Hospitals NHS Foundation Trust with a proposal to part fund a Da Vinci surgical robot. After the YAC board being shown a presentation which demonstrated this innovative technology they agreed to fund. Surgery performed via the surgical robot is less invasive than open surgery, allowing better precision in difficult to access areas than traditional key‐hole surgery, leading to fewer complications, shorter recovery times and overall better outcomes. The board agreed to contribute £680k towards the instruments, training and running costs covering the period 2022‐23 to 2024‐25; not only does this provide the Trust with a brilliant surgical instrument but it is an investment in advanced technology. By June the robot was fully operational, and it was reported that its value was already being seen.

www.yorkagainstcancerorg.uk 5

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

The board of Trustees decided that providing support to local cancer patients via a cancer support Centre was much needed and to create such a facility away from the hospital setting would be a great asset for anyone affected by cancer.

The board agreed to a 10‐year lease and set a budget for the fit‐out and adaptation of the space.

The whole process was supported by a project team including designers, project management team, builders and including a YAC project team who met fortnightly to make decisions and deal with any issues or concerns as they arose. The project took most of 2022 and with a completion date within the first quarter of 2023.

www.yorkagainstcancerorg.uk 6

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2022 this funding enabled 6 new studies to commence, they were looking at a variety of cancers, cancer genetics and early cancer detection. There are also an additional 13 cancer studies open, 12 of these quickly hit the target number of recruits which would not have been achieved without the YAC funded personnel. The YAC posts also help support some of our long‐ standing studies, at present there are 25 studies in follow up, many of these studies have 10+ year follow ups.

Excitingly, there are another 14 studies about to be set up in the coming months, and these are in the areas of Haematology, Bowel, Breast, and Head and Neck cancer.

Jack Birch Unit (University of York)

The Charity is committed to another 1 year and 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: ‐

Director of the Jack Birch Unit Assistant Director Laboratory technician Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2022

The Jack Birch Unit published five research papers in scientific journals this year, covering various aspects of our research. This included a paper presenting evidence supporting Dr Simon Baker’s theory that bladder cancer may be caused by a virus. The importance of this work resulted in Simon then being invited to speak at conferences in Palm Springs, Edinburgh and Cambridge!

In March, several of us took part in the 4th Bladder Cancer Translational Research Meeting in London. Then, in October, several members of the team journeyed to Barcelona to the International Bladder Cancer Network conference. Andrew Mason gave a well‐ received talk, whilst PhD students Ryan Elliott and Vlad Ungureanu presented posters about their research. Andrew and Vlad also presented to the Northern Bioinformatics User Group (NorthernBUG) in Bradford, where Andrew discussed how data from bladder cancer samples can be used to inform patient treatment. Andrew has now finished his YAC‐sponsored independent fellowship and moved into the University lectureship position agreed at the time of his appointment. As a result, “cancer informatics” (including large data handling and analysis) is being embedded in biomedical teaching and research at the University and I would like to highlight the critical role that YAC has played in this transformation. Andrew will continue as a key member of the JBU team for his future research.

Dr Simon Baker with the rest of the JBU team in 2022

www.yorkagainstcancerorg.uk 7

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

In October, Rachael Moore joined us as a PhD student funded by the Medical Research Council. She is investigating Natural Killer cells and their role in eliminating cancerous cells from normal tissues. During the year we had several undergraduate and masters students working with us, including Lexy (Denise) Barrazza, originally from Mexico, who stayed on as a research assitant after the completion of her Master’s course. We said farewell to two longstanding members of staff: Dr Jenny Hinley took up training to be a midwife and Dr Jo Pearson took a break and has since returned to work with another cancer group. To fill the vacancy left, we promoted Raphael Slip as our new Technical Team Manager for the JBU. Amongst other activities, several JBU staff took part in the YAC awareness days held in May and October and several female members took part in March in the International Day of Women and Girls in Science.

One of the highlights this year was the conferring of an honorary degree by the University of York to Professor Steve Leveson in recognition of his career in surgery, his role as a cofounder of York Against Cancer and his contribution to the research of the Jack Birch Unit. The University is organising an event for all fundraisers in 2023.

Last, but not least, I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

----- Start of picture text -----
Prof Steve Leveson on
Graduation Day.
----- End of picture text -----

Professor Jenny Southgate, Director,

Jack Birch Unit of Molecular Carcinogenesis, University of York

www.yorkagainstcancerorg.uk 8

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2022

I would like to thank my fellow members of the group who have continued to work hard during 2022. Our small but committed team has continued to hold hybrid meetings, face to face and zoom.

The Enthuse partnership restarted in May after being stalled due to Covid. Simon Baker has worked closely with the STEM team and with the teachers from participating schools. The focus was to gather data from the schools and to produce relevant lesson plans and to arrange teacher visits the JBU labs and the YAC offices to enable them to find out more about both organisations.

We distributed 911 sun hats to 24 primary schools in the York and surrounding area. Our committed volunteers assisted with the delivery to the participating schools.

We held two awareness days during 2022, in May at the community stadium and in October in the City Centre, both were successful.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our recent focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included both awareness days.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

As the focus of the group is awareness it was decided the group should be renamed Awareness and Education.

Thank you to the YAC team and the Awareness and Education group members.

Lynn Bartram

Chair, Education and Awareness group

www.yorkagainstcancerorg.uk 9

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful ‘shop front’ for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much‐needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2022 in relation to its fundraising activities.

Fundraising report 2022

This year we have been able to con�nue rebuilding our fundraising ac�vi�es which has been a very exci�ng �me for York Against Cancer. We have been able to have more of our regular events again including our awareness days, the golf day and York Rocks Against Cancer. We were so pleased to be able to hold the York Against Cancer Christmas Lunch again this year and also have our in‐town Awareness Day – it has been fantas�c to see everyone again at all of our events over the course of the year.

As well as holding our own events we have been supported brilliantly by our volunteers, the general public and local businesses who have fundraised for us in various ways including, sponsored walks, head shaves, pantomimes and The Press Cash for Charity ini�a�ve. We are also always incredibly grateful to be supported by our volunteers who have helped us this year by a�ending events, par�cipa�ng in can collec�ons, holding stalls, working in our shops, baking and dona�ng goods for us to sell.

Overall, we have been able to get a lot of our events back in the diary and resume a sense of normality. We are very much looking forward to the next year, fundraising at our established events as well as new opportuni�es including The Yorkshire 10 Mile and The Total Warrior.

I’d like to take the opportunity to say a big thank you to all of our amazing supporters, with their hard work and efforts York Against Cancer is able to con�nue what it set out to do – care for, support and educate the people of York and the surrounding areas and also fund ground‐breaking research in The Jack Birch Unit at The University of York.

Lauren Hudson

Head of Fundraising and Executive Assistant

www.yorkagainstcancerorg.uk 10

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub‐group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub‐group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long‐term plans and services the charity provides can be continued into the foreseeable future.

Future projects to operate out of the Leveson Centre include: ‐

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision‐ making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

www.yorkagainstcancerorg.uk 11

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Organisational Structure

The Board delegates the day‐to‐day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell General Manager, from 4 April CEO Heather Atkinson Office & Accounts Manager, from 4 April Deputy CEO and Head of Finance Lauren Hudson Personal Assistant to General Manager, from 4 April Head of Fundraising Nicola Doherty Office & Volunteer coordinator, from 4 April Head of Administration and Volunteer coordinator Jill Hutchinson Head of Retail from 7 March Jenna Hunton Retail Assistant from 11 May Hayley Johnson Head of Engagement P/T until 17 November Neil Johnson Minibus Driver P/T Garry Stanton Minibus Driver P/T

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three‐year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re‐elected for a further 3‐year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity’s two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

www.yorkagainstcancerorg.uk 12

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review and polices

The Charity’s funds in 2022 decreased by £380,991 (2021 ‐ increased by £495,416). Prior to any adjustment for investments, the Charity made a deficit of £351,405 (2021 ‐ surplus of £109,854). The largest commitments in the year were: ‐

The detail of funding of projects can be found in note 6.

The principal funding sources are fund‐raising, the trading shops, donations, and legacies. Gross income in 2022 amounted to £1,468,175 (2021 £647,704). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the ‘free reserves’ should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity’s funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2022. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2022, before fees, was ‐7.53% (2021 10.99%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2022, before fees, was 7.4% (2021 11.80%).

www.yorkagainstcancerorg.uk 13

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2022 are £4,397,069 (2021 £4,778,060).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,151,686 (2021 £3,041,746). These have decreased as the trustees have designated significant funds to the Leveson Centre, Jack Birch Unit and Health Welfare. The level of free reserves is £725,888 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 14 months of our budgeted undesignated operating costs. It is the charity’s policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £3,109,980 (2021 £1,597,671) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £135,403 (2021 £138,643) details of which are given in Note 17 to the financial statements.

www.yorkagainstcancerorg.uk 14

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors’ and Trustees’ responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company’s state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

Approved by the Board on 6 June 2023 and signed on its behalf by:

Ian Yeowart Director and Trustee

www.yorkagainstcancerorg.uk 15

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference and administrative details

Registered Charity number 1130835 Company Limited number 06884476 by Guarantee Principal Office and Trading Address East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF

Principal Office and Trading Address

Company Secretary Julie Pamela Russell

Directors and Trustees Andrew Proctor Dr Lynn Bartram Angela Darby Michael Sweet Rachel Goddard Robert Onyett Michael John Stower Tarnia Hudson William Mark Sessions Prof Stephen Leveson Ian Yeowart Michael Patrick Shepherd Sarah Wearing

Trustee’s protocol available on request

Accountants HPH Auditors Hentons & Co LLP Chartered Accountants Chartered Accountants 54 Bootham 124 Acomb Road York Holgate YO30 7XZ York YO24 4EY Bankers National Westminster Bank Solicitors Harrowells 1 Market Street Moorgate House York Clifton Moorgate YO1 8SR York YO30 4WY Investment Advisors HSBC Global Asset Ruffer LLP Management 80 Victoria Street 78 St James’s Street London London SW1E 5JL SW1A 1EJ

www.yorkagainstcancerorg.uk 16

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2022

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the ‘group’) for the year ended 31 December 2022 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

www.yorkagainstcancerorg.uk 17

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2022

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

www.yorkagainstcancerorg.uk 18

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2022

Irregularities, including fraud, are instances of non‐compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

www.yorkagainstcancerorg.uk 19

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2022

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

………………………………………………..

Brett Davis (Senior Statutory Auditor)

For and on behalf of Hentons & Co LLP

Chartered Accountants Statutory Auditor 124 Acomb Road York YO24 4EY

Date: 6 June 2023

www.yorkagainstcancerorg.uk 20

YORK AGAINST CANCER

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2022

Note
Income and endowments from:
Donations and legacies
2
Other trading activities
3
Investments
4
Total
Expenditure on:
Raising funds
5
Charitable activities
6
Total
Net income/(expenditure)
before gains on investments
Net (losses)/gains on investments
11
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
1,154,842
-
261,895
-
36,438
-
1,453,175
-
259,611
-
1,503,518
40,711
1,763,129
40,711
(309,954)
(40,711)
(29,586)
-
(339,540)
(40,711)
(1,550,520)
1,553,020
(1,890,060)
1,512,309
3,041,746
1,597,671
1,151,686
£
3,109,980
£
Unrestricted		 Restricted
Funds
£
15,000
-
-
15,000
-
15,740
15,740
(740)
-
(740)
(2,500)
(3,240)
138,643
135,403
£		 Year ended
31 Dec
2022
£
1,169,842
261,895
36,438
1,468,175
259,611
1,559,969
1,819,580
(351,405)
(29,586)
(380,991)
-
(380,991)
4,778,060
4,397,069
£		 Year ended
31 Dec
2021
£
403,515
199,087
45,102
647,704
199,970
337,880
537,850
109,854
385,562
495,416
-
495,416
4,282,644
4,778,060
£

The notes on pages 24 to 34 form part of these financial statements.

21

YORK AGAINST CANCER (Registration number: 06884476)

BALANCE SHEET AS AT 31 DECEMBER 2022

FIXED ASSETS
Tangible Fixed Assets
12
Investments
11
CURRENT ASSETS
Stock
Debtors
13
Cash at Bank and in Hand
CREDITORS: amounts falling due
within one year
14
TOTAL ASSETS LESS CURRENT
LIABILITIES
CREDITORS: amounts falling due
after one year
15
NET ASSETS
THE FUNDS OF THE CHARITY
Unrestricted
Undesignated
18
Designated
16,18
Restricted
17,18
TOTAL CHARITY FUNDS
NET CURRENT ASSETS
Note		 Charity
2022
£
826,241
3,516,498
4,342,739
-
1,043,825
811,874
1,855,699
1,055,560
800,139
5,142,878
731,410
£ 4,411,468
1,206,074
3,069,991
135,403
£ 4,411,468		 Consolidated
2022
£
866,230
3,516,497
4,382,727
60,521
912,677
863,649
1,836,847
1,091,095
745,752
5,128,479
731,410
£ 4,397,069
1,151,686
3,109,980
135,403
4,397,069
£		 Charity
2021
£
362,264
4,076,185
4,438,449
-
540,858
819,603
1,360,461
498,519
861,942
5,300,391
537,202
£ 4,763,189
3,069,782
1,554,764
138,643
£ 4,763,189		 Consolidated
2021
£
405,171
4,076,184
4,481,355
55,176
449,771
846,463
1,351,410
517,503
833,907
5,315,262
537,202
£ 4,778,060
3,041,746
1,597,671
138,643
£ 4,778,060

Approved by the Trustees on 6 June 2023 and signed on its behalf by:

S B Wearing Director and Trustee

The notes on pages 24 to 34 form part of these financial statements.

22

YORK AGAINST CANCER CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

Note
Cash flows from operating activities:
Net cash used in operating activities
21
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of property, plant and equipment
Proceeds from sale of property
Proceeds from sales of investments
Purchase of investments
Net cash provided by investing activities
Change in cash and cash equivalents in the
reporting period
Cash and cash equivalents at the beginning of
the reporting period
Cash and cash equivalents at the end of
the reporting period		 2022
£
(226,911)
36,438
(322,442)
-
1,475,082
(944,981)
244,097
17,186
846,463
£ 863,649		 2021
£
(335,263)
45,102
(64,330)
251,731
1,838,749
(1,788,361)
282,891
(52,372)
898,835
£ 846,463

The notes on pages 24 to 34 form part of these financial statements.

23

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

24

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property at straight line over 50 years or life of lease Equipment - Shop and office equipment at straight line over 10 years - Computer equipment at straight line over 3 years - Respite home equipment at straight line over 4 years - Motor vehicles at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2022. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

25

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

2.

NATIONS AND LEGACIES
In Memoriam
Legacies
Government grant
Intangible income
Donations and grants		 Unrestricted
Restricted
2022
£
£
£
213,697
15,000
228,697
26,509
-
26,509
909,636
-
909,636
-
-
-
5,000
-
5,000
£ 1,154,842
£ 15,000
£ 1,169,842		 2021
£
158,533
19,852
206,699
13,431
5,000
£ 403,515

DONATIONS AND LEGACIES

During the year the charity was notified of a potential further £157,000 in legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES

HER TRADING ACTIVITIES
Fundraising income
Subsidiary's non-charitable trading turnover
ESTMENTS
Interest received
Dividends received
ALYSIS OF RAISING FUNDS
Advertising
Fundraising costs
Non charitable trading - other costs
Non charitable trading - staff costs
Non charitable trading - depreciation
Investment fees		 Unrestricted
Restricted
£
£
6,639
-
80,727
-
115,039
-
34,601
-
5,405
-
17,200
-		 2022
£
136,121
125,774
£ 261,895
2022
£
1,210
35,228
£ 36,438
2022
£
6,639
80,727
115,039
34,601
5,405
17,200
£ 259,611		 2021
£
99,601
99,486
£ 199,087
2021
£
627
44,475
£ 45,102
2021
£
11,292
36,933
110,546
21,123
5,156
14,920
£ 259,611
£ -		 £ 199,970

4. INVESTMENTS

5. ANALYSIS OF RAISING FUNDS

26

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

6. ANALYSIS OF CHARITABLE ACTIVITES

Direct project costs: Unrestricted Restricted 2022 2021
£ £ £ £
Research
Jack Birch Unit 353,262 10,000 363,262 -
Clinical Trial Nurses 152,221 - 152,221 95,051
Support and Care
Cancer Care Centre - Old - - - 6,511
Leveson Centre 37,378 - 37,378 -
Respite property expenses 22,653 - 22,653 21,103
Minibus running costs - direct 11,882 - 11,882 12,248
Minibus running costs - staff costs 21,273 - 21,273 20,439
Mobile Chemotherapy Unit* - 5,740 5,740 (104,381)
Transport - Rapid diagnostics 7,086 - 7,086 -
Psychology services 10,805 - 10,805 4,040
Robotic surgery 680,000 - 680,000 -
One off costs 150 - 150 -
Health Care Assistant - - - 12,818
Health Welfare Advisor - - - 73,444
Education
Education expenses 8,850 - 8,850 2,588
1,305,560 15,740 1,321,300 143,861
*During 2021 the underspend on the Mobile Chemotherapy Unit was released as the project cost less than intially budgeted. Running
costs will be covered by the restricted funds in future years.
Support costs:
Staff costs 154,175 - 154,175 139,079
Staff training and travel 3,666 - 3,666 2,553
Rent, service charge and rates 16,871 - 16,871 21,779
Heat and light 3,756 - 3,756 1,837
Repairs and maintenance 1,510 - 1,510 173
Insurances 4,318 - 4,318 3,416
Printing, stationery and postage 4,913 - 4,913 4,870
Computer expenses 11,516 - 11,516 7,819
Telephone 800 - 800 2,693
Sundry expenses 4,176 - 4,176 6,384
Gains and losses on fixed assets - - - (28,554)
Depreciation 19,370 - 19,370 16,168
225,071 - 225,071 178,217
Governance costs:
Audit fees 4,560 - 4,560 4,560
Accountancy fees 7,400 - 7,400 7,507
Legal fees - - - 2,182
Bank charges 1,638 -
 1,638
 1,553
13,598 - 13,598 15,802
Total charitable activities £ 1,544,229 £ 15,740 £ 1,559,969 £ 337,880

27

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

7. NET INCOMING RESOURCES FOR THE YEAR
NET INCOMING RESOURCES FOR THE YEAR 2022 2021
£ £
This is stated after charging:
Depreciation 24,775 21,324
Auditor's remuneration for audit services - charity 4,560 4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

AFF COSTS
Wages and salaries
Social security costs
Pension costs
Recruitment costs
Medical Insurance		 2022
£
185,048
11,194
7,602
3,120
3,085
£ 210,049		 2021
£
160,955
8,614
6,701
-
4,371
£ 180,641

The average monthly head count was 8 staff (2021 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects 1 1
Trading 1 1
Management and administration 6 6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £88,781 (2021 - £50,303).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the

There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £138,024 (2021 £92,808). Interest of £nil (2021 £186) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

ummary of the results of the subsidiary is shown below:
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Other operating income
Interest payable
Profit on ordinary activities before taxation
Taxation
Profit on ordinary activities after taxation
Amount gifted to York Against Cancer
Retained (withdrawn from)/within Subsidiary
Net Assets		 2022
£
125,774
(61,578)
64,196
(93,467)
(29,271)
-
-
(29,271)
-
(29,271)
-
£ (29,271)
£ (14,399)		 2021
£
99,486
(64,071)
35,415
(72,754)
(37,339)
15,333
(186)
(22,192)
-
(22,192)
-
£ (22,192)
£ 14,871

28

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

11. INVESTMENTS

ESTMENTS
Consolidated
Market value at 1 January 2022
Additions at cost
Disposals
Revaluations
Market value at 31 December 2022
Analysis of investments by class:
Listed investments
The historical cost of the above investments amounts to:		 2022
£
4,076,184
944,981
(1,475,082)
(29,586)
£ 3,516,497
£ 3,516,497
£ 3,196,719		 2021
£
3,741,010
1,788,361
(1,838,749)
385,562
£ 4,076,184
£ 4,076,184
£ 3,633,156

The following material investments are over 5% by value of the investments held

Ruffer Charity Assets Trust Account 2022
Market value
£
1,832,547
£ 1,832,547		 2021
Market value
£
2,231,923
£ 2,231,923

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

TANGIBLE FIXED ASSETS
Cost
Additions in year
Disposals in year
At 31 December 2022
At 31 December 2022
Depreciation
At 31 December 2021
At 1 January 2022
Charge for year
Disposals in year
At 31 December 2022
Net book value
At 1 January 2022		 Subsidiary -
Motor
Charity
Shop
Property
Vehicles
Equipment
Total
Equipment
£
£
£
£
£
367,702
41,515
40,333
449,550
51,561
432,228
46,936
4,183
483,347
2,487
-
(673)
(673)
799,930
88,451
43,843
932,224
54,048
36,771
37,342
13,173
87,286
8,654
7,354
5,880
6,136
19,370
5,405
-
(673)
(673)
44,125
43,222
18,636
105,983
14,059
£ 755,805
£ 45,229
£ 25,207
£ 826,241
£ 39,989
£ 330,931
£ 4,173
£ 27,160
£ 362,264
£ 42,907		 Consolidated
Total
£
501,111
485,834
(673)
986,272
95,940
24,775
(673)
120,042
£ 866,230
£ 405,171

All fixed assets are held for direct charitable purposes in Designated Funds.

29

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

13.
Amounts owed by subsidiary
Prepayments
Accrued income
Other debtors
14. CREDITORS: amounts falling due
within one year
Trade creditors
Project creditors
Taxation and social security
Accruals
Other creditors
15. CREDITORS: amounts falling due
after one year
Project creditors
DEBTORS		 Charity
Consolidated
Charity
Consolidated
2022
2022
2021
2021
£
£
£
£
138,024
-
92,809
-
13,396
20,272
6,488
6,596
892,405
892,405
430,000
430,000
-
-
11,561
13,175
£ 1,043,825
£ 912,677
£ 540,858
£ 449,771
176,204 182,320 2,445 3,488
827,466
827,466 476,711
476,711
3,802
4,201 3,146
6,325
45,342
74,362 14,187
28,949
2,746
2,746
2,030
2,030
£ 1,055,560
£ 1,091,095
£ 498,519
£ 517,503
£ 731,410
£ 731,410
£ 537,202
£ 537,202

16.[DESIGNATED FUNDS (consolidated)]

Designated Funds - 2022
Leveson Centre
On demand services
Education Project
Minibus
Health Welfare
Jack Birch Unit
Robotic Surgery Project
Fixed Assets Fund
Total
Designated Funds - 2021
Leveson Centre
On demand services
Education Project
Minibus
Robotic Surgery Project
Fixed Assets
Complementary Therapy
Cancer Care Centre
Total		 Balance
Income
Expenditure
Transfers
Balance
01/01/2022
31/12/2022
£
£
£
£
£
466,500
-
-
87,250
553,750
10,000
-
(7,086)
63,086
66,000
-
-
(8,850)
18,850
10,000
36,000
-
-
(36,000)
-
-
-
-
114,000
114,000
-
-
-
1,500,000
1,500,000
680,000
-
-
(680,000)
-
405,171
-
(24,775)
485,834
866,230
£ 1,597,671
£ -
£ (40,711)
£ 1,553,020
£ 3,109,980
Balance
Income
Expenditure
Transfers
Balance
01/01/2021
31/12/2021
£
£
£
£
£
-
466,500
466,500
10,000
-
-
-
10,000
-
-
(2,588)
2,588
-
28,000
-
-
8,000
36,000
-
-
-
680,000
680,000
585,342
-
7,230
(187,401)
405,171
6,364
-
(6,364)
-
-
5,382
-
(5,382)
-
-
£ 635,088
£ -
£ (7,104)
£ 969,687
£ 1,597,671

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

30

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

16.[DESIGNATED FUNDS (consolidated continued)]

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diaognositics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in the year.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in the current year and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Cancer Care Centre

The Board was committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2022
Mobile Chemotherapy Unit
Minibus Appeal
Jack Birch Unit
Mouth Cancer
Total 2022
Restricted Funds - 2021
Mobile Chemotherapy Unit
Mouth Cancer
Total 2021		 Balance
Income
Expenditure
Transfers
Balance
01/01/2022
31/12/2022
£
£
£
£
£
136,966
2,500
(5,740)
-
133,726
-
2,500
-
(2,500)
-
-
10,000
(10,000)
-
-
1,677
-
-
-
1,677
£ 138,643
£ 15,000
(£ 15,740)
(£ 2,500)
£ 135,403
Balance
Income
Expenditure
Transfers
Balance
01/01/2021
31/12/2021
£
£
£
£
£
142,348
-
(5,382)
-
136,966
1,677
-
-
-
1,677
£ 144,025
£ -
(£ 5,382)
£ -
£ 138,643

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the purchase of a new minibus which was purchased in the year.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during the year.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

31

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2022
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Fund balances at 31 December 2021
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities		 General
Designated
Restricted
Total
Funds
Funds
Funds
2022
£
£
£
£
-
866,230
-
866,230
2,016,497
1,500,000
-
3,516,497
957,694
743,750
135,403
1,836,847
(1,091,095)
-
-
(1,091,095)
(731,410)
-
-
(731,410)
£ 1,151,686
£ 3,109,980
£ 135,403
£ 4,397,069
General
Designated
Restricted
Total
Funds
Funds
Funds
2021
£
£
£
£
-
405,171
-
405,171
4,076,184
-
-
4,076,184
1,163,021
49,746
138,643
1,351,410
(517,503)
-
-
(517,503)
(537,202)
-
-
(537,202)
£ 4,184,500
£ 454,917
£ 138,643
£ 4,778,060

19. OPERATING LEASE COMMITMENTS

As at 31 December 2022 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

At 31 December 2022 At 31 December 2022 At 31 December 2021 At 31 December 2021
Land and Office Land and Office
buildings equipment buildings equipment
Total operating leases payable: £ £ £ £
Within one year 115,905 - 40,298 -
Between two and five years 335,370 - 45,684 -
After five years 278,273 - 2,486 -

20. RELATED PARTIES

During the year the Charitable Company paid £3,097 (2021 £2,829) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2021 £107) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £nil (2021 £2,160) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Directorr, Robert Onyett, is a director.

During 2021 the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover. No payments were made in 2022.

During the year trustees and related parties donated £116,384 (2021 £50,100) to the charity.

32

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

21. CASH FLOW NOTES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation charges
Gains on sale of fixed assets
(Gains)/Losses on investments
Dividends, interest and rents from investments
(Increase)/Decrease in stocks
Increase in debtors
(Increase)/Decrease in creditors
Net cash used in operating activities
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash at bank and in hand
Total cash and cash equivalents
ANALYSIS OF CHANGES IN NET DEBT
At
01/01/2022
£
Cash
846,463
RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES		 2022
2021
£
£
(380,991)
495,416
24,775
21,324
-
(28,554)
29,586
(385,562)
(36,438)
(45,102)
(5,345)
119
(462,906)
12,514
604,408
(405,418)
£ (226,911)
£ (335,263)
863,649
846,463
£ 863,649
£ 846,463
At
Cash-flows
31/12/2022
£
£
15,542
862,005

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

33

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

24. COMPARATIVE INFORMATION

Income and endowments from:
Donations and legacies
Other trading activities
Investments
Total
Expenditure on:
Raising funds
Charitable activities
Total
Net expenditure
before losses on investments
Net gains on investments
Net income/(expenditure)
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
403,515
-
199,087
-
45,102
-
647,704
-
199,970
-
325,394
7,104
525,364
7,104
122,340
(7,104)
385,562
-
507,902
(7,104)
(969,687)
969,687
(461,785)
962,583
3,503,531
635,088
£ 3,041,746
£ 1,597,671
Unrestricted		 Restricted
Funds
£
-
-
-
-
-
5,382
5,382
(5,382)
-
(5,382)
-
(5,382)
144,025
£ 138,643		 Year ended
31 Dec
2021
£
403,515
199,087
45,102
647,704
199,970
337,880
537,850
109,854
385,562
495,416
-
495,416
4,282,644
£ 4,778,060

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £250,000 for the completion of the Leveson Centre fit out. These funds have been designated.

34